Mirum’s Livmarli Now Approved for PFIC in Patients 12 Months and Older

KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema

drugs.com - 03/Sep 20:09

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Sep. 3, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the U.S....

KalVista announces FDA acceptance of NDA for sebetralstat for oral on-demand treatment of HAE

haei.org - 03/Sep 17:29

KalVista announces FDA acceptance of New Drug Application for sebetralstat for oral on-demand treatment of hereditary angioedema KalVista...

WellSync and Marius Pharmaceuticals Collaborate to Offer FDA-approved Oral Testosterone Replacement Therapy, Expanding Virtual Care for Men's Health

healthtechzone.com - 09/Sep 11:00

Mirum Pharmaceuticals (MIRM) Up 4.5% Since Last Earnings Report: Can It Continue?

zacks.com - 06/Sep 15:31

Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zynex Stock Rises on FDA Clearance of Its New Pain Management Device

zacks.com - 04/Sep 12:32

ZYXI recently received the Food and Drug Administration clearance for its new TensWave device. TensWave is designed to provide a comprehensive pain...

Tremfya (guselkumab) Receives U.S. FDA Approval for Adults with Moderately to Severely Active Ulcerative Colitis

drugs.com - 13/Sep 07:09

HORSHAM, Pa. (September 11, 2024) – Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved...

Tremfya (guselkumab) Receives U.S. FDA Approval for Adults with Moderately to Severely Active Ulcerative Colitis

drugs.com - 13/Sep 07:09

HORSHAM, Pa. (September 11, 2024) – Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved...

A More Efficient FDA Approval Process: An Expert’s Proposal

theparadise.ng - 06/Sep 00:50

The Food and Drug Administration (FDA), as many are aware, is the leading entity for the regulation and safety testing for foods and pharmaceuticals...

FDA Approves Tremfya for Ulcerative Colitis

drugs.com - 22:24

MONDAY, Sept. 16, 2024 -- The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for the treatment of adults with moderately to...

FDA Approves Tremfya for Ulcerative Colitis

drugs.com - 22:24

MONDAY, Sept. 16, 2024 -- The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for the treatment of adults with moderately to...

Rubriques :

Mirum’s Livmarli Now Approved for PFIC in Patients 12 Months and Older

Articles similaires

KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema

KalVista announces FDA acceptance of NDA for sebetralstat for oral on-demand treatment of HAE

WellSync and Marius Pharmaceuticals Collaborate to Offer FDA-approved Oral Testosterone Replacement Therapy, Expanding Virtual Care for Men's Health

Mirum Pharmaceuticals (MIRM) Up 4.5% Since Last Earnings Report: Can It Continue?

Zynex Stock Rises on FDA Clearance of Its New Pain Management Device

Tremfya (guselkumab) Receives U.S. FDA Approval for Adults with Moderately to Severely Active Ulcerative Colitis

Tremfya (guselkumab) Receives U.S. FDA Approval for Adults with Moderately to Severely Active Ulcerative Colitis

A More Efficient FDA Approval Process: An Expert’s Proposal

FDA Approves Tremfya for Ulcerative Colitis

FDA Approves Tremfya for Ulcerative Colitis

Les derniers communiqués